The RELIEF study: Tolerability and efficacy of preservative-free latanoprost in the treatment of glaucoma or ocular hypertension.

In an initial preclinical in vitro study of this formulation, the viability of human corneal epithelial cells after 24 h of treatment was slightly reduced, to 83% of cells treated with phosphate-buffered saline (PBS), but this did not reach statistical significance; by contrast, BAK-latanoprost or 0.02% BAK induced a significant decrease in cellular viability (p < 0.05 versus PBS). 8 Furthermore, in an animal corneo-conjunctival surface model, PBS and PF-latanoprost showed the lowest toxicities, whereas BAK-latanoprost and 0.02% BAK induced significant toxic

also in 111,027 other papers